Ritlecitinib Tosylate Patent Expiration

Ritlecitinib Tosylate was first introduced by Pfizer Inc in its drug Litfulo on Jun 23, 2023.


Ritlecitinib Tosylate Patents

Given below is the list of patents protecting Ritlecitinib Tosylate, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Litfulo US12116368 Pyrrolo[2,3-d]pyrimidine tosylate salt, crystalline form thereof and manufacturing process and intermediates thereto Oct 17, 2041 Pfizer
Litfulo US12077533 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides Dec 03, 2034 Pfizer
Litfulo US9617258 Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides Dec 03, 2034 Pfizer



Ritlecitinib Tosylate's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List